Group 1 - Pacira BioSciences, Inc. is committed to delivering innovative, non-opioid pain therapies to transform patients' lives [1][2] - The company has three commercial-stage non-opioid treatments: EXPAREL®, ZILRETTA®, and ioveraº® [2] - Pacira is advancing the development of PCRX-201, a novel locally administered gene therapy for treating prevalent diseases like osteoarthritis [2] Group 2 - Pacira will participate in the Raymond James 46th Annual Institutional Investors Conference on March 5th at 10:25 AM ET [3] - The company will also attend the Barclays 27th Annual Global Healthcare Conference on March 12th at 8:00 AM ET [3]

Core Viewpoint - Wall Street analysts anticipate Pacira (PCRX) will report quarterly earnings of $0.86 per share, reflecting a year-over-year decline of 3.4%, while revenues are expected to be $184.01 million, an increase of 1.5% from the previous year [1] Earnings Projections - Changes in earnings projections are crucial for predicting investor reactions to the stock, with empirical studies showing a strong correlation between earnings estimate trends and short-term stock price movements [2] Analyst Forecasts - Analysts project that 'Revenue- Net product sales- EXPAREL' will reach $145.33 million, indicating a year-over-year change of +1% [4] - The consensus for 'Revenue- Net product sales- ZILRETTA' is $30.72 million, reflecting a +7% change from the year-ago quarter [4] - For 'Revenue- Net product sales- iovera', analysts estimate $6.36 million, which represents a +5.4% change from the previous year [4] Total Revenue Estimates - The combined estimate for 'Revenue- Total net product sales' is projected to be $183.38 million, indicating a year-over-year change of +2% [5] Stock Performance - Pacira shares have seen a -1.6% change over the past month, compared to a -1.8% move in the Zacks S&P 500 composite, with a Zacks Rank 1 (Strong Buy) suggesting expected outperformance in the near future [5]

Core Viewpoint - Pacira BioSciences, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between August 2, 2023, and August 8, 2024 [1] Group 1: Lawsuit Details - The lawsuit was initiated following a press release on August 9, 2024, where Pacira announced the invalidation of its U.S. Patent No. 11,033,495 related to its main product Exparel, which constitutes approximately 80% of the company's revenue [2] - The invalidation of the '495 patent raises concerns about the validity of other patents held by Pacira, potentially leading to increased competition from generic products and higher litigation costs [2] - Following the announcement, Pacira's stock price plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 14, 2025, to request appointment as lead plaintiff in the lawsuit [3] - Participation in the lawsuit does not require investors to incur any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - Pacira BioSciences, Inc. faces significant legal challenges following the invalidation of its key patent, which could lead to increased competition and financial losses for the company [1]. Summary by Relevant Sections Company Overview - Pacira BioSciences, Inc. (NASDAQ: PCRX) is primarily known for its product Exparel, which constitutes approximately 80% of its revenue [1]. Legal Issues - A lawsuit against eVenus resulted in the court ruling that Pacira's U.S. Patent No. 11,033,495 (the '495 patent) is not valid, meaning eVenus is not infringing on it [1]. - The invalidation of the '495 patent raises concerns about the validity of Pacira's other patents, potentially leading to more generic competitors entering the market and increased litigation costs [1]. Stock Performance - Following the announcement of the patent invalidation, Pacira's stock price plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [1]. Shareholder Actions - Shareholders who purchased shares during the class period from August 2, 2023, to August 8, 2024, are encouraged to register for a class action lawsuit, with a deadline for lead plaintiff appointment set for March 14, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. Legal Representation - The Gross Law Firm is leading the class action, emphasizing its commitment to protecting investors' rights against deceitful business practices [3].

Core Viewpoint - Pacira BioSciences, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between August 2, 2023, and August 8, 2024, following the invalidation of a key patent that significantly impacts its revenue [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by the alleged fraud during the specified period [1]. - On August 9, 2024, Pacira announced that its U.S. Patent No. 11,033,495, crucial for its product Exparel, was deemed invalid, leading to concerns about the validity of other patents and potential market competition from generics [2]. - Following the patent invalidation announcement, Pacira's stock plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until March 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Pacira BioSciences, Inc. is set to report its fourth quarter and full year financial results for 2024 on February 27, 2025, after U.S. market close, followed by a live conference call [1] Company Overview - Pacira specializes in innovative, non-opioid pain therapies aimed at transforming patient lives [3] - The company has three commercial-stage non-opioid treatments: - EXPAREL®: a long-acting local analgesic for various postsurgical pain management applications [3] - ZILRETTA®: an extended-release injection for osteoarthritis knee pain management [3] - ioveraº®: a handheld device providing immediate, long-acting, drug-free pain control through cold temperature [3] - Pacira is also developing PCRX-201, a novel gene therapy targeting prevalent diseases like osteoarthritis [3]

Core Viewpoint - Pacira BioSciences, Inc. is facing a class action securities lawsuit due to alleged securities fraud that has adversely affected investors between August 2, 2023, and August 8, 2024 [1] Group 1: Lawsuit Details - The lawsuit is a response to a press release issued by Pacira on August 9, 2024, which announced the invalidation of its U.S. Patent No. 11,033,495 related to Exparel, a product that generates approximately 80% of the company's revenue [2] - Following the announcement, Pacira's stock price plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 14, 2025, to request the Court to appoint them as lead plaintiff, although participation does not require serving in this role [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - Pacira BioSciences, Inc. is facing a class action securities lawsuit due to alleged securities fraud that has significantly impacted its stock price following the invalidation of a key patent [1][2]. Group 1: Lawsuit Details - The class action lawsuit aims to recover losses for investors affected by alleged securities fraud between August 2, 2023, and August 8, 2024 [1]. - On August 9, 2024, Pacira announced that its U.S. Patent No. 11,033,495, crucial for its product Exparel, was deemed invalid, leading to concerns about the validity of other patents and potential market competition [2]. - Following the patent invalidation announcement, Pacira's stock plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 14, 2025, to request appointment as lead plaintiff in the lawsuit [3]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

Core Viewpoint - Pacira BioSciences, Inc. faces significant legal challenges following the invalidation of its key patent, which could lead to increased competition and financial losses for the company [1]. Summary by Relevant Sections Legal Issues - Pacira's U.S. Patent No. 11,033,495, crucial for its product Exparel, was ruled invalid by the court, impacting approximately 80% of the company's revenue [1]. - The invalidation raises concerns about the validity of other patents held by Pacira, potentially allowing more generic competitors to enter the market [1]. Stock Performance - Following the announcement of the patent ruling, Pacira's stock price plummeted from $22.36 per share on August 8, 2024, to a low of $11.70 per share on August 9, 2024, marking a decline of over 47% in just one day [1]. Shareholder Actions - Shareholders who purchased shares during the class period from August 2, 2023, to August 8, 2024, are encouraged to register for a class action lawsuit, with a deadline for lead plaintiff appointment set for March 14, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2].

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/pacira-biosciences-inc-lawsui ...